Life Sciences,
Journal Year:
2023,
Volume and Issue:
320, P. 121558 - 121558
Published: March 6, 2023
Glioma
is
the
most
common
tumor
of
primary
central
nervous
system,
and
its
malignant
phenotype
has
been
shown
to
be
closely
related
glioma
stem
cells
(GSCs).
Although
temozolomide
significantly
improved
therapeutic
outcome
with
a
high
penetration
rate
blood-brain
barrier,
resistance
often
present
in
patients.
Moreover,
evidence
that
crosstalk
between
GSCs
tumor-associated
microglia/macrophages
(TAMs)
affect
clinical
occurrence,
growth,
multi-tolerance
chemoradiotherapy
gliomas.
Here,
we
highlight
vital
roles
maintenance
stemness
ability
recruit
TAMs
microenvironment
promote
their
polarization
into
tumor-promoting
macrophages,
hence
providing
groundwork
for
future
research
new
treatment
strategies
cancer.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(14), P. 13333 - 13347
Published: July 5, 2023
Glioblastomas
(GBMs)
are
aggressive
primary
brain
tumors
with
fatal
outcome.
Traditional
chemo-radiotherapy
has
poor
therapeutic
effect
and
significant
side
effects,
due
to
the
drug
radiotherapy
(RT)
resistance,
natural
blood-brain
barrier,
high-dose
RT
damage.
Even
more,
tumor-associated
monocytes
(macrophages
microglia,
TAMs)
constitute
up
30%-50%
of
GBM
cellular
content,
tumor
microenvironment
(TME)
in
is
extremely
immunosuppressive.
Here,
we
synthesized
nanoparticles
(D@MLL)
that
hitchhike
on
circulating
target
intracranial
GBMs
assistance
low-dose
RT.
The
chemical
construction
D@MLL
was
DOX·HCl
loaded
MMP-2
peptide-liposome,
which
could
by
surface
modified
lipoteichoic
acid.
First,
at
site
increases
monocyte
chemotaxis
induces
M1
type
polarization
TAMs.
Subsequently,
intravenous
injected
targets
hitchhikes
them
central
area.
then
released
response,
inducing
immunogenic
cell
death,
releasing
calreticulin
high-mobility
group
box
1.
This
further
contributed
TAMs
M1-type
polarization,
dendritic
maturation,
T
activation.
study
demonstrates
advantages
delivered
endogenous
sites
after
RT,
it
provides
a
high-precision
treatment
for
GBMs.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(2), P. 843 - 884
Published: Jan. 4, 2023
Immunotherapy
continues
to
be
in
the
spotlight
of
oncology
therapy
research
past
few
years
and
has
been
proven
a
promising
option
modulate
one's
innate
adaptive
immune
systems
for
cancer
treatment.
However,
poor
delivery
efficiency
agents,
potential
off-target
toxicity,
nonimmunogenic
tumors
significantly
limit
its
effectiveness
extensive
application.
Recently,
emerging
biomaterial-based
drug
carriers,
including
but
not
limited
cells
bacteria,
are
expected
candidates
break
dilemma
immunotherapy,
with
their
excellent
natures
intrinsic
tumor
tropism
immunomodulatory
activity.
More
than
that,
tiny
vesicles
physiological
components
derived
from
them
have
similar
functions
source
due
inheritance
various
surface
signal
molecules
proteins.
Herein,
we
presented
representative
examples
about
latest
advances
employed
cells,
derivatives.
Simultaneously,
opportunities
challenges
bacteria-based
carriers
discussed
provide
reference
future
application
immunotherapy.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
36(7)
Published: Sept. 15, 2023
Abstract
Brain
diseases,
such
as
brain
tumors,
neurodegenerative
cerebrovascular
and
injuries,
are
caused
by
various
pathophysiological
changes,
which
pose
a
serious
health
threat.
disorders
often
difficult
to
treat
due
the
presence
of
blood–brain
barrier
(BBB).
Biomimetic
nanovesicles
(BNVs),
including
endogenous
extracellular
vesicles
(EVs)
derived
from
cells
artificial
nanovesicles,
possess
ability
penetrate
BBB
thus
can
be
utilized
for
drug
delivery
brain.
BNVs,
especially
EVs,
widely
distributed
in
body
fluids
usually
carry
disease‐related
signal
molecules
proteins,
RNA,
DNA,
may
also
analyzed
understand
etiology
pathogenesis
diseases.
This
review
covers
exhaustive
classification
characterization
BNVs
roles
involved
emphatically
focuses
on
nanotechnology‐integrated
disease
theranostics,
diagnosis
strategies
precise
therapeutic
regulations
(e.g.,
immunity
regulation,
disordered
protein
clearance,
anti‐neuroinflammation,
neuroregeneration,
angiogenesis,
gut–brain
axis
regulation).
The
remaining
challenges
future
perspectives
regarding
treatment
diseases
discussed
outlined.
Small,
Journal Year:
2023,
Volume and Issue:
19(45)
Published: July 7, 2023
Abstract
Glioblastoma
is
one
of
the
most
aggressive
central
nervous
system
malignancies
with
high
morbidity
and
mortality.
Current
clinical
approaches,
including
surgical
resection,
radiotherapy,
chemotherapy,
are
limited
by
difficulty
targeting
brain
lesions
accurately,
leading
to
disease
recurrence
fatal
outcomes.
The
lack
effective
treatments
has
prompted
researchers
continuously
explore
novel
therapeutic
strategies.
In
recent
years,
nanomedicine
made
remarkable
progress
expanded
its
application
in
drug
delivery,
providing
a
new
treatment
for
tumors.
Against
this
background,
article
reviews
delivery
systems
paper,
mechanism
nanomaterials
crossing
blood‐brain
barrier
summarized.
Furthermore,
specific
nanotechnology
glioblastoma
discussed
depth.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Nov. 8, 2023
Glioma
is
the
most
prevalent
brain
tumor,
presenting
with
limited
treatment
options,
while
patients
malignant
glioma
and
glioblastoma
(GBM)
have
poor
prognoses.
The
physical
obstacle
to
drug
delivery
imposed
by
blood‒brain
barrier
(BBB)
stem
cells
(GSCs),
which
are
widely
recognized
as
crucial
elements
contributing
unsatisfactory
clinical
outcomes.
In
this
study,
we
found
a
small
molecule,
gambogic
amide
(GA-amide),
exhibited
ability
effectively
penetrate
blood-brain
displayed
notable
enrichment
within
tumor
region.
Moreover,
GA-amide
significant
efficacy
in
inhibiting
growth
across
various
vivo
models,
encompassing
transgenic
primary
patient-derived
xenograft
(PDX)
models.
We
further
performed
genome-wide
clustered
regularly
interspaced
short
palindromic
repeats
(CRISPR)
knockout
screen
determine
druggable
target
of
GA-amide.
By
combination
cellular
thermal
shift
assay
(CETSA),
affinity
responsive
stability
(DARTS)
approach,
molecular
docking
simulation
surface
plasmon
resonance
(SPR)
analysis,
WD
repeat
domain
1
(WDR1)
was
identified
direct
binding
Through
interaction
WDR1,
promoted
formation
complex
involving
MYH9
Cofilin,
accelerate
depolymerization
F-actin
inhibit
invasion
(PDCs)
induce
PDC
apoptosis
via
mitochondrial
apoptotic
pathway.
conclusion,
our
study
not
only
an
effective
safe
agent
for
treating
but
also
shed
light
on
underlying
mechanisms
from
perspective
cytoskeletal
homeostasis.
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(8), P. 6445 - 6462
Published: Feb. 15, 2024
Tumor-associated
macrophages
(TAMs)
are
closely
related
to
the
progression
of
glioblastoma
multiform
(GBM)
and
its
development
therapeutic
resistance
conventional
chemotherapy.
TAM-targeted
therapy
combined
with
chemotherapy
has
emerged
as
a
promising
strategy
combat
GBM.
However,
presence
blood–brain
barrier
(BBB)
severely
limits
efficacy.
Meanwhile,
lack
ability
distinguish
different
targeted
cells
also
poses
challenge
for
precise
therapy.
Herein,
we
propose
cathepsin
B
(CTSB)-responsive
programmed
brain-targeted
delivery
system
(D&R-HM-MCA)
simultaneous
GBM-targeted
delivery.
D&R-HM-MCA
could
cross
BBB
via
low
density
lipoprotein
receptor-associated
protein
1
(LRP1)-mediated
transcytosis.
Upon
reaching
GBM
site,
outer
angiopep-2
modification
be
detached
from
cleavage
CTSB-responsive
peptide,
which
circumvent
abluminal
LRP1-mediated
efflux.
The
exposed
p-aminophenyl-α-d-mannopyranoside
(MAN)
further
recognize
glucose
transporter-1
(GLUT1)
on
macrophage
mannose
receptor
(MMR)
TAMs.
achieve
chemotherapeutic
killing
simultaneously
induce
TAM
polarization
anti-inflammatory
M2
phenotype
pro-inflammatory
M1
phenotype,
thus
resensitizing
response
improving
anti-GBM
immune
response.
This
not
only
can
improve
brain
efficiency,
but
enable
combination
chemo-immunotherapy
against
effectiveness
this
may
provide
thinking
designing
more
functional
systems
effective
regimens.
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
13(20)
Published: April 23, 2024
Gliomas,
the
most
prevalent
primary
brain
tumors,
pose
considerable
challenges
due
to
their
heterogeneity,
intricate
tumor
microenvironment
(TME),
and
blood-brain
barrier
(BBB),
which
restrict
effectiveness
of
traditional
treatments
like
surgery
chemotherapy.
This
review
provides
an
overview
engineered
cell
membrane
technologies
in
glioma
therapy,
with
a
specific
emphasis
on
targeted
drug
delivery
modulation
immune
microenvironment.
study
investigates
progress
membranes,
encompassing
physical,
chemical,
genetic
alterations,
improve
across
BBB
effectively
target
gliomas.
The
examination
focuses
interaction
membrane-coated
nanoparticles
(ECM-NPs)
TME
gliomas,
emphasizing
potential
modulate
behavior
enhance
therapeutic
efficacy.
further
explores
involvement
ECM-NPs
immunomodulation
techniques,
highlighting
impact
reactions.
While
facing
obstacles
related
stability
manufacturing
scalability,
outlines
forthcoming
research
directions
focused
enhancing
performance.
underscores
promise
surpassing
conventional
constraints,
proposing
novel
approaches
for
efficacious
treatment.
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
13(18)
Published: March 21, 2024
Glioblastoma
multiforme
(GBM)
is
the
most
aggressive
brain
cancer,
characterized
by
a
rapid
and
drug-resistant
progression.
GBM
"builds"
around
its
primary
core
genetically
heterogeneous
tumor-microenvironment
(TME),
recruiting
surrounding
healthy
cells
releasing
various
intercellular
signals.
Glioma-associated
microglia
(GAM)
represent
largest
population
of
collaborating
cells,
which,
in
TME,
usually
exhibit
anti-inflammatory
M2
phenotype,
thus
promoting
an
immunosuppressing
environment
that
helps
tumor
growth.
Conversely,
"classically
activated"
M1
could
provide
proinflammatory
antitumorigenic
activity,
expected
to
exert
beneficial
effect
defeating
glioblastoma.
In
this
work,
immunotherapy
approach
based
on
modulation
GAM
phenotype
proposed,
through
controlled
localized
electrical
stimulation.
The
developed
strategy
relies
wireless
ultrasonic
excitation
polymeric
piezoelectric
nanoparticles
coated
with
cell
membrane
extracts,
exploit
homotypic
targeting
antiglioma
applications.
Such
camouflaged
nanotransducers
locally
generate
cues
membranes,
activating
their
ultimately
triggering
promising
anticancer
activity.
Collected
findings
open
new
perspectives
immune
activities
"smart"
nanomaterials
and,
more
specifically,
innovative
auspicious
tool
glioma
immunotherapy.
Military Medical Research,
Journal Year:
2024,
Volume and Issue:
11(1)
Published: March 29, 2024
Abstract
Drug
delivery
systems
(DDS)
have
recently
emerged
as
a
promising
approach
for
the
unique
advantages
of
drug
protection
and
targeted
delivery.
However,
access
nanoparticles/drugs
to
central
nervous
system
(CNS)
remains
challenge
mainly
due
obstruction
from
brain
barriers.
Immune
cells
infiltrating
CNS
in
pathological
state
inspired
development
strategies
foundation
Herein,
we
outline
three
major
barriers
mechanisms
by
which
immune
migrate
across
blood–brain
barrier.
We
subsequently
review
biomimetic
utilizing
cell-based
nanoparticles
CNS,
well
recent
progress
rationally
engineering
DDS
diseases.
Finally,
discuss
challenges
opportunities
diseases
promote
their
clinical
development.
